AVIR Stock Overview
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Atea Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.72 |
| 52 Week High | US$5.19 |
| 52 Week Low | US$2.77 |
| Beta | 0.16 |
| 1 Month Change | -9.27% |
| 3 Month Change | 4.20% |
| 1 Year Change | 13.41% |
| 3 Year Change | -89.78% |
| 5 Year Change | n/a |
| Change since IPO | -87.74% |
Recent News & Updates
Recent updates
Atea wins FDA Fast Track status for dengue treatment
Sep 26Atea Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
May 13
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Jan 05Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
Nov 25A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Oct 20U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs
Jun 17Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 15Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
May 13Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Apr 08Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
Mar 06Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares
Jan 30
Shareholder Returns
| AVIR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.1% | -2.3% | -3.7% |
| 1Y | 13.4% | 11.4% | 20.2% |
Return vs Industry: AVIR exceeded the US Pharmaceuticals industry which returned 11.4% over the past year.
Return vs Market: AVIR underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| AVIR volatility | |
|---|---|
| AVIR Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AVIR has not had significant price volatility in the past 3 months.
Volatility Over Time: AVIR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 75 | Jean-Pierre Sommadossi | ateapharma.com |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19.
Atea Pharmaceuticals, Inc. Fundamentals Summary
| AVIR fundamental statistics | |
|---|---|
| Market cap | US$313.09m |
| Earnings (TTM) | -US$135.96m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs AVIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVIR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$70.09m |
| Gross Profit | -US$70.09m |
| Other Expenses | US$65.87m |
| Earnings | -US$135.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AVIR perform over the long term?
See historical performance and comparison